Top section
Top section
Never mind that your desk had a great year, writes Craig. When it comes to getting paid, the future makes a stronger argument than the past
Top 25 shareholders and new investors participate in previously delayed offering, but some shares left over after subscriptions closed
Undisclosed institutional shareholder sells stake in Wednesday evening ABB
More articles
More articles
More articles
-
Hong Kong has had its first taste of a pre-revenue biotechnology stock with the listing by Ascletis Pharma. Unfortunately, the company got caught up in a wave of volatility and the shares have not fared well. It was not a good start for biotech but the sector should not be judged by this one deal, as it was just the first from a bulging IPO pipeline. -
Haidilao International Holding plans to launch its $1bn IPO in Hong Kong by the end of the month, according to bankers working on the deal.
-
Shanghai Junshi Biosciences is eyeing a $500m IPO in Hong Kong, having filed a draft prospectus with the city’s stock exchange.
-
Italy’s new coalition government has not been kind to its equity capital markets, with IPOs especially hindered by uncertainty. Unless there is a dramatic change, ECM bankers do not expect much improvement in the autumn.
-
Victoria, the UK flooring firm, has completed a £60.5m ($77.77m) sale of new shares to fund its takeover of Saloni, a Spanish producer of high-end tiles.
-
Investors are returning to emerging market assets, stemming the tide of outflows from a sector battered by an international trade dispute and strong dollar — but perhaps only briefly.
Sub-sections
shared comment list
